LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary
care services, today launched a partnership with ASCEND
Therapeutics US, LLC, a subsidiary of Besins Healthcare and a
specialty pharmaceutical company concentrating on women's health,
to provide integrated telehealth services to improve access to
EstroGel® 0.06% (estradiol gel). LifeMD’s telehealth services are
now accessible on ASCEND Therapeutics’ brand website,
www.estrogel.com, allowing patients to connect with a LifeMD
affiliated provider.
“This agreement with ASCEND Therapeutics, a global
market leader improving women’s lives with a focus on innovative
hormone therapies, is an example of an increasing number of
pharmaceutical partnerships applying LifeMD technology and aptitude
in consumer healthcare engagement,” said Justin Schreiber, Chairman
and Chief Executive Officer of LifeMD. “By providing patient access
to a high-quality physician at the moment they are searching for
treatment, we are removing barriers to care – like lengthy
appointment wait times and risk of inconsistent care by less
experienced practitioners – while also improving health outcomes by
providing on-demand and ongoing access to primary care
providers.”
Besins Healthcare is a global leader in hormone
therapy with a 33% share of the global progesterone market, which
is poised to surpass $2.4 billion by 2030 at a CAGR of 13%.1 Besins
Healthcare is also recognized as the world leader in testosterone
replacement therapy, a market that is expected to reach $2.2
billion by 2027 at a CAGR of 4.6%.2 ASCEND Therapeutics’ EstroGel®
is an FDA-approved bioidentical estrogen gel applied to the skin —
one pump, applied to one arm, once a day — that can help manage
some of the symptoms of menopause.3 Among surveyed women, 89%
prefer EstroGel® over their previous hormone therapy.4
“Menopause is a natural part of aging, but
countless women are dealing with symptoms that are having a
negative impact on their daily lives. We are excited about our
partnership with LifeMD, as it will provide a digital front door to
our patients, promoting access to healthcare solutions that
restore, restart and regulate fundamental female body processes,”
said Cyrille Labourel, Chief Executive Officer of ASCEND
Therapeutics. “We look forward to a continued partnership with
LifeMD, including similar market strategies in support of AndroGel®
1% and 1.62%, and a potential joint venture that would provide
access to a broader set of men’s and women’s hormonal
therapies.”
1 Global Progesterone Market Demand, Size &
Share to Surpass USD 2136 Million by 2030, Bloomberg, January 2023.
2 Testosterone Replacement Therapy Global Market Report 2023, The
Business Research Company, May 2023.3 EstroGel® [package insert].
Herndon, VA: ASCEND Therapeutics; 2020.4 In a survey sponsored by
ASCEND Therapeutics, 89% of 620 women using EstroGel® after a
previous therapy said that they prefer EstroGel® over their
previous therapy.
About LifeMDLifeMD is a leading
provider of virtual primary care. LifeMD offers telemedicine,
laboratory and pharmacy services, and specialized treatment across
more than 200 conditions, including primary care, men’s health,
women’s health, allergy & asthma, and dermatology. Leveraging a
vertically-integrated, proprietary digital care platform, a
50-state affiliated medical group, and a US-based patient care
center, LifeMD is elevating healthcare by increasing access to
top-notch and affordable care. For more information, please visit
LifeMD.com.
Cautionary Note Regarding
Forward-Looking
StatementsThis news release includes forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended; Section 21E of the Securities Exchange Act of
1934, as amended; and the safe harbor provision of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this news release may be identified by the
use of words such as: “believe,” “expect,” “anticipate,” “project,”
“should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,”
“continue,” and “potential,” or, in each case, their negative or
other variations or comparable terminology referencing future
periods. Examples of forward-looking statements include, but are
not limited to, statements regarding our financial outlook and
guidance, short and long-term business performance and operations,
future revenues and earnings, regulatory developments, legal events
or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products
and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations
or financial condition.
Forward-looking statements are not historical facts
and are not assurances of future performance. Rather, these
statements are based on our current expectations, beliefs, and
assumptions regarding future plans and strategies, projections,
anticipated and unanticipated events and trends, the economy, and
other future conditions, including the impact of any of the
aforementioned on our future business. As forward-looking
statements relate to the future, they are subject to inherent risk,
uncertainties, and changes in circumstances and assumptions that
are difficult to predict, including some of which are out of our
control. Consequently, our actual results, performance, and
financial condition may differ materially from those indicated in
the forward-looking statements. These risks and uncertainties
include, but are not limited to, “Risk Factors” identified in our
filings with the Securities and Exchange Commission, including, but
not limited to, our most recently filed Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and any amendments thereto. Even if
our actual results, performance, or financial condition are
consistent with forward-looking statements contained in such
filings, they may not be indicative of our actual results,
performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news
release is based on information currently available to us as of the
date on which this release is made. We undertake no obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or otherwise, except as may be
required under applicable law or regulation.
Media Contact:press@lifemd.com
Company Contact:LifeMD, Inc.Marc
Benathen, CFOmarc@lifemd.com
Grafico Azioni LifeMD (NASDAQ:LFMDP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni LifeMD (NASDAQ:LFMDP)
Storico
Da Giu 2023 a Giu 2024